Alfuzosin

Drug Profile

Alfuzosin

Alternative Names: Alfetim Retard; Alfoten; Alfuzosin hydrochloride; Benestan; Dilotex; Mittoval; SL 77499; SL 7749910; Urion; Uroxatral; Uroxatrol; Xatral; Xatral OD; Xatral Retard; Xatral SR; Xatral XL

Latest Information Update: 18 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Quinazolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Urination disorders
  • Discontinued Bladder dysfunction

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2013 Alfuzosin licensed to Covis Pharma for commercialization in USA
  • 30 Jan 2013 NovaMed Pharmaceuticals renews its marketing license for alfuzosin in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top